On this page, you will learn:
- How NUVAXOVID is ready to use, with no dilution, mixing, or thawing required1
- That NUVAXOVID can be stored in a standard refrigerator1
- Who is eligible for the vaccine
NUVAXOVID arrives ready to use in pre-filled syringes, with no freezing or thawing needed1
Ready to use—no dilution, mixing, or thawing required
Ships in a carton of 10 pre-filled syringes, each containing 1 dose of 0.5 mL1
Store in a standard refrigerator
Store pre-filled syringes between 2 to 8 °C (36 to 46 °F)1
Can be coadministered with a seasonal flu vaccine
According to the CDC, COVID-19 and flu vaccines can be administered at the same appointment2
Follow the recommended dosing schedule when administering NUVAXOVID1,3,4
For patients aged 65+
Vaccinated with primary series of NUVAXOVID or with any other COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose at least 2 months after receipt of the previous COVID-19 vaccine dose1
- ACIP recommends patients should receive an additional dose 6 months after the previous dose (minimum interval of 2 months)3
Not previously vaccinated with any COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose1
- ACIP recommends patients should receive an additional dose 6 months after the previous dose (minimum interval of 2 months)3
For patients aged 12-64 with ≥1 underlying condition
Vaccinated with primary series of NUVAXOVID or with any other COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose at least 2 months after receipt of the previous COVID-19 vaccine dose1
Not previously vaccinated with any COVID-19 vaccine
- NUVAXOVID is administered intramuscularly as a single 0.5 mL dose1
Are your high-risk patients eligible for NUVAXOVID?
The NUVAXOVID pivotal trial included patients who were high risk for COVID-19 due to underlying conditions, including chronic lung disease, cardiovascular disease, chronic liver disease, severe obesity, and diabetes.1
You can access the FDA's policy position on COVID-19 vaccination to see the list of medical conditions that increase risk of severe COVID-19. For further information, consult your national and local health authorities.
NUVAXOVID uses the same protein-based technology as certain modern flu vaccines.1,5
ACIP = Advisory Committee on Immunization Practices; CDC = Centers for Disease Control and Prevention.
INDICATION
References
1. NUVAXOVID. Prescribing Information. Novavax, Inc; 2025. 2. Centers for Disease Control and Prevention. Getting a flu vaccine and other recommended vaccines at the same time. September 2024. Accessed February 1, 2026. https://www.cdc.gov/flu/vaccines/coadministration.html 3. Roper LE, Godfrey M, Link-Gelles R, et al. Use of additional doses of 2024-2025 COVID-19 vaccine for adults aged ≥65 years and persons aged ≥6 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(49):1118-1123. 4. Panagiotakopoulos L, Moulia DL, Godfrey M, et al. Use of COVID-19 vaccines for persons aged ≥6 months: recommendations of the Advisory Committee on Immunization Practices—United States, 2024-2025. MMWR Morb Mortal Wkly Rep. 2024 Sep 19;73(37):819-824. doi:10.15585/mmwr.mm7337e2 5. Centers for Disease Control and Prevention. Recombinant influenza (flu) vaccine. September 9, 2024. Accessed May 7, 2026. https://www.cdc.gov/fl u/vaccine-types/fl ublok-vaccine.html
